Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 126.1
(-0.98%)
INR 126.1
(-0.98%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.15 Billion INR | -37.96% |
| 2022 | 8.3 Billion INR | 196.38% |
| 2021 | 2.8 Billion INR | 21.94% |
| 2020 | 2.29 Billion INR | -15.73% |
| 2019 | 2.72 Billion INR | -31.6% |
| 2018 | 3.98 Billion INR | 29.04% |
| 2017 | 3.08 Billion INR | 12.69% |
| 2016 | 2.74 Billion INR | 68.47% |
| 2015 | 1.62 Billion INR | 14.01% |
| 2014 | 1.42 Billion INR | -22.27% |
| 2013 | 1.83 Billion INR | -12.18% |
| 2012 | 2.08 Billion INR | 144.08% |
| 2011 | 856.26 Million INR | 10.49% |
| 2010 | 774.98 Million INR | 7.28% |
| 2009 | 722.38 Million INR | 17.36% |
| 2008 | 615.52 Million INR | 0.07% |
| 2007 | 615.09 Million INR | 11.31% |
| 2006 | 552.57 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.2 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 6.67 Billion INR | 0.0% |
| 2023 Q4 | 5.15 Billion INR | 0.0% |
| 2023 FY | 5.15 Billion INR | -37.96% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 8.3 Billion INR | 196.38% |
| 2022 Q4 | 8.3 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 2.92 Billion INR | 0.0% |
| 2021 Q2 | 2.95 Billion INR | 0.0% |
| 2021 Q4 | 2.8 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 2.8 Billion INR | 21.94% |
| 2020 FY | 2.29 Billion INR | -15.73% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.49 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 2.29 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 2.72 Billion INR | 0.0% |
| 2019 FY | 2.72 Billion INR | -31.6% |
| 2019 Q2 | 2.72 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 3.98 Billion INR | 0.0% |
| 2018 Q2 | 3.48 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 3.98 Billion INR | 29.04% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 3.08 Billion INR | 12.69% |
| 2017 Q4 | 3.08 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.45 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 2.74 Billion INR | 0.0% |
| 2016 FY | 2.74 Billion INR | 68.47% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 3.58 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 1.62 Billion INR | 14.01% |
| 2015 Q2 | 1.68 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 1.62 Billion INR | 0.0% |
| 2014 Q4 | 1.42 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.42 Billion INR | -22.27% |
| 2014 Q2 | 1.67 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 2.01 Billion INR | 0.0% |
| 2013 Q4 | 1.83 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 1.83 Billion INR | -12.18% |
| 2012 Q4 | 2.08 Billion INR | 0.0% |
| 2012 FY | 2.08 Billion INR | 144.08% |
| 2011 FY | 856.26 Million INR | 10.49% |
| 2011 Q4 | 856.26 Million INR | 0.0% |
| 2010 FY | 774.98 Million INR | 7.28% |
| 2009 FY | 722.38 Million INR | 17.36% |
| 2008 FY | 615.52 Million INR | 0.07% |
| 2007 FY | 615.09 Million INR | 11.31% |
| 2006 FY | 552.57 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -68.87% |
| Aarti Drugs Limited | 24.32 Billion INR | 78.826% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 80.053% |
| Ajanta Pharma Limited | 46.38 Billion INR | 88.896% |
| Alembic Limited | 23.28 Billion INR | 77.884% |
| Alkem Laboratories Limited | 155.74 Billion INR | 96.693% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 92.009% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 52.224% |
| Bal Pharma Limited | 3.2 Billion INR | -60.755% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -993.905% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 57.57% |
| Brooks Laboratories Limited | 904.45 Million INR | -469.449% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -248.75% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 80.906% |
| Divi's Laboratories Limited | 154.7 Billion INR | 96.671% |
| Eris Lifesciences Limited | 70.48 Billion INR | 92.693% |
| Granules India Limited | 55.2 Billion INR | 90.671% |
| Ind-Swift Limited | 6.54 Billion INR | 21.304% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -137.26% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 87.105% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 95.54% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -114.545% |
| Medicamen Biotech Limited | 2.94 Billion INR | -74.873% |
| Medico Remedies Limited | 961.95 Million INR | -435.411% |
| Wockhardt Limited | 76.49 Billion INR | 93.267% |
| Orchid Pharma Limited | 15.53 Billion INR | 66.854% |
| RPG Life Sciences Limited | 5.12 Billion INR | -0.423% |
| Shilpa Medicare Limited | 30.93 Billion INR | 83.349% |
| Sigachi Industries Limited | 6.94 Billion INR | 25.803% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 78.052% |
| Unichem Laboratories Limited | 31.69 Billion INR | 83.749% |
| Vaishali Pharma Limited | 799.55 Million INR | -544.157% |
| Wanbury Limited | 3.43 Billion INR | -49.942% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 98.241% |
| FDC Limited | 24.68 Billion INR | 79.132% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -40.387% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 32.686% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.671% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 81.931% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 55.795% |
| Laurus Labs Limited | 83.87 Billion INR | 93.859% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -54.47% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 76.494% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -406.874% |
| Hester Biosciences Limited | 6.62 Billion INR | 22.24% |
| Ipca Laboratories Limited | 111.01 Billion INR | 95.361% |
| Venus Remedies Limited | 6.26 Billion INR | 17.834% |
| ZIM Laboratories Limited | 4.46 Billion INR | -15.267% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.857% |
| Morepen Laboratories Limited | 12.93 Billion INR | 60.173% |
| Neuland Laboratories Limited | 18.32 Billion INR | 71.895% |
| Sequent Scientific Limited | 15.4 Billion INR | 66.564% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 77.151% |
| Valiant Laboratories Limited | 3.42 Billion INR | -50.294% |
| Windlas Biotech Limited | 6.26 Billion INR | 17.752% |
| Hikal Limited | 24.87 Billion INR | 79.292% |
| Innova Captab Limited | 13.2 Billion INR | 61.008% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 35.163% |
| Themis Medicare Limited | 5.66 Billion INR | 9.07% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 77.052% |
| Mankind Pharma Limited | 119.63 Billion INR | 95.695% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 96.413% |
| Sakar Healthcare Limited | 3.88 Billion INR | -32.517% |
| Albert David Limited | 4.97 Billion INR | -3.423% |
| Lupin Limited | 239.97 Billion INR | 97.854% |
| Gufic Biosciences Limited | 10.92 Billion INR | 52.859% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.397% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | 26.453% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -27.276% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.377% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 96.58% |
| NATCO Pharma Limited | 69.06 Billion INR | 92.542% |
| Suven Life Sciences Limited | 2.84 Billion INR | -80.778% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -189.065% |
| Strides Pharma Science Limited | 58.39 Billion INR | 91.18% |
| Indoco Remedies Limited | 21.44 Billion INR | 75.986% |
| Alpa Laboratories Limited | 1.82 Billion INR | -182.026% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -241.383% |